# MedEcon: Cost-Effectiveness Analysis Tool

**Document Type**: Project Specification  
**Last Updated**: [Current Date]  
**Status**: Draft  
**Sharing**: Restricted to Project Team

---

## 1. Executive Summary

This document outlines the specifications for MedEcon, a web-based tool for conducting cost-effectiveness analyses of medical treatments. The platform aims to help healthcare stakeholders evaluate both clinical efficacy and economic impact of emerging medical treatments, enabling evidence-based decision making.

The MVP (Minimum Viable Product) focuses on core functionality for analyzing individual treatments against standard comparators, with plans for more advanced features in future iterations.

---

## 2. Project Overview

### 2.1 Problem Statement

Healthcare stakeholders face challenges when evaluating new treatments:
- Clinical efficacy data is often disconnected from economic impact assessment
- Cost-effectiveness analyses are complex and time-consuming
- Specialized expertise is required to interpret results
- Visualization tools for communicating findings are limited

### 2.2 Solution Approach

MedEcon addresses these challenges by providing:
- An integrated platform combining clinical and economic data
- User-friendly interface requiring minimal specialized knowledge
- Automated calculations and threshold-based recommendations
- Interactive visualizations and exportable reports

### 2.3 Target Users

| User Group | Description | Primary Needs |
|------------|-------------|---------------|
| Healthcare Providers | Hospital administrators, clinical directors, P&T committees | Treatment procurement decisions, resource allocation |
| Payers | Insurance companies, government agencies, MCOs | Coverage policies, reimbursement rates |
| Manufacturers | Pharmaceutical companies, device manufacturers, biotech firms | Value demonstration, pricing strategies |
| Researchers | Health economists, academic researchers, policy analysts | Comparative analyses, publication support |

---

## 3. Feature Requirements

### 3.1 MVP Features

| ID | Feature | Description | Priority |
|----|---------|-------------|----------|
| F1 | Dashboard | Overview of recent analyses with summary metrics | High |
| F2 | New Analysis Form | Data entry for treatment parameters | High |
| F3 | ICER Calculation | Core algorithm for cost-effectiveness ratio | High |
| F4 | Results Visualization | Interactive charts for analysis results | High |
| F5 | Sensitivity Analysis | Parameter variation impact assessment | Medium |
| F6 | Export Functionality | PDF report generation | Medium |
| F7 | Local Storage | Save analyses to browser storage | Low |

### 3.2 Future Features

| ID | Feature | Description | Priority |
|----|---------|-------------|----------|
| F8 | Treatment Database | Library of standard treatments | Medium |
| F9 | Advanced Modeling | Markov models, Monte Carlo simulations | Medium |
| F10 | Multi-user Collaboration | Shared analyses and comments | Low |
| F11 | Data Integration | EHR and clinical trial database connections | Low |
| F12 | Cloud Storage | Server-side data persistence | Medium |
| F13 | Batch Analysis | Multiple treatment comparison | Low |

---

## 4. Technical Specifications

### 4.1 Architecture

The MVP will use a client-side architecture:
- HTML5 for structure
- CSS3 with Bootstrap for responsive design
- Vanilla JavaScript for logic
- Chart.js for data visualization

Future versions may incorporate:
- Backend server (Node.js/Express)
- Database (MongoDB)
- Authentication system
- API integrations

### 4.2 Data Model

#### 4.2.1 Treatment Analysis

```javascript
{
  id: String,                    // Unique identifier
  name: String,                  // Treatment name
  comparator: String,            // Comparator treatment
  
  // Clinical parameters
  qalyGain: Number,              // QALY gain (vs comparator)
  successRate: Number,           // % success rate
  adverseEventRate: Number,      // % adverse event rate
  treatmentDuration: Number,     // Duration in months
  
  // Economic parameters
  treatmentCost: Number,         // Direct treatment cost
  administrationCost: Number,    // Administration cost
  monitoringCost: Number,        // Monitoring cost
  adverseEventCost: Number,      // Cost per adverse event
  
  // Results
  incrementalCost: Number,       // Calculated incremental cost
  icer: Number,                  // Calculated ICER
  recommendation: String,        // Cost-effectiveness recommendation
  
  // Metadata
  createdAt: Date,               // Creation timestamp
  updatedAt: Date                // Last update timestamp
}
```

#### 4.2.2 Thresholds

```javascript
{
  highlyEffective: Number,       // Threshold for highly cost-effective ($/QALY)
  potentiallyEffective: Number   // Threshold for potentially cost-effective ($/QALY)
}
```

### 4.3 Key Algorithms

#### 4.3.1 ICER Calculation

```
// Calculate total costs for new treatment
totalCostNew = treatmentCost + administrationCost + monitoringCost + (adverseEventCost * adverseEventRate / 100)

// Comparator cost is either provided or assumed
totalCostComparator = comparatorCost

// Calculate incremental cost
incrementalCost = totalCostNew - totalCostComparator

// Calculate ICER
icer = incrementalCost / qalyGain
```

#### 4.3.2 Sensitivity Analysis

The sensitivity analysis varies key parameters by percentage increments (e.g., 70% to 130% of base case) to evaluate the impact on ICER.

---

## 5. User Interface Design

### 5.1 Key Screens

#### 5.1.1 Dashboard
- Recent analyses list with ICER badges
- Cost-effectiveness scatter plot
- Quick action buttons (New Analysis)

#### 5.1.2 Analysis Form
- Treatment information section
- Clinical efficacy inputs
- Economic data inputs
- Action buttons (Cancel, Run Analysis)

#### 5.1.3 Results View
- Cost-effectiveness summary table
- Sensitivity analysis chart
- Cost breakdown chart
- Action buttons (Edit, Save, Export)

### 5.2 Design Principles

- Clean, professional aesthetic appropriate for healthcare setting
- Responsive design for desktop and tablet use
- Clear visual hierarchy with emphasis on key metrics
- Color coding based on cost-effectiveness thresholds
- Accessible design with sufficient contrast

### 5.3 Mockups

Mockups are available in the design folder:
- dashboard.png
- analysis-form.png
- results-view.png

---

## 6. Testing Strategy

### 6.1 Test Cases

| ID | Test Case | Description | Expected Result |
|----|-----------|-------------|-----------------|
| T1 | Form Validation | Enter invalid data in analysis form | Error messages displayed |
| T2 | ICER Calculation | Run analysis with test data | ICER matches expected value |
| T3 | Recommendation | Analysis with different ICER values | Correct recommendation badge |
| T4 | Sensitivity Chart | Run analysis with test data | Chart displays correct variations |
| T5 | Local Storage | Save and reload an analysis | Analysis data persists |

### 6.2 User Testing

Initial user testing will focus on:
- Form usability
- Results interpretation
- Visual clarity of charts
- Recommendation understanding

---

## 7. Implementation Plan

### 7.1 MVP Development Phases

| Phase | Description | Timeline |
|-------|-------------|----------|
| 1 | Core UI Framework and Navigation | Week 1 |
| 2 | Analysis Form Implementation | Week 2 |
| 3 | Calculation Engine | Week 3 |
| 4 | Results Visualization | Week 4 |
| 5 | Storage and Export | Week 5 |
| 6 | Testing and Refinement | Week 6 |

### 7.2 Future Development Roadmap

| Release | Features | Timeline |
|---------|----------|----------|
| 1.0 | MVP Features (F1-F7) | Month 3 |
| 1.1 | Treatment Database (F8) | Month 5 |
| 2.0 | Cloud Storage (F12) | Month 8 |
| 2.5 | Advanced Modeling (F9) | Month 12 |
| 3.0 | Multi-user Collaboration (F10) | Month 18 |

---

## 8. Success Metrics

| Metric | Target | Measurement Method |
|--------|--------|-------------------|
| User Engagement | 70% completion rate | Form completion tracking |
| Analysis Accuracy | <5% error rate | Validation against manual calculations |
| User Satisfaction | >4/5 average rating | Post-use surveys |
| Time Efficiency | 75% time reduction | Comparison with manual process |

---

## 9. Appendices

### 9.1 Glossary

- **QALY**: Quality-Adjusted Life Year
- **ICER**: Incremental Cost-Effectiveness Ratio
- **CEA**: Cost-Effectiveness Analysis
- **WTP**: Willingness to Pay (threshold)

### 9.2 References

1. Neumann, P. J., & Cohen, J. T. (2018). QALYs in 2018—Advantages and Concerns. JAMA, 319(24), 2473-2474.
2. Sanders, G. D., et al. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA, 316(10), 1093-1103.
3. Drummond, M. F., et al. (2015). Methods for the economic evaluation of health care programmes. Oxford University Press.

### 9.3 Document History

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 0.1 | [Initial Date] | [Author] | Initial draft |
| 0.2 | [Date] | [Author] | Added technical specifications |
| 0.3 | [Date] | [Author] | Added testing strategy |

---

*This document is confidential and contains proprietary information. Unauthorized distribution is prohibited.* 